Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis

• Published in: OncoTargets and therapy Vol. 11; pp. 955 - 965
• Main Authors: Sacdalan, Danielle Benedict, Lucero, Josephine Anne, Sacdalan, Dennis
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2018; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Adenosine; Analysis; Antigens; Apoptosis; Biological markers; Biomarkers; Cancer; Cancer research; Colorectal cancer; Development and progression; Genotype & phenotype; Growth factors; Immune checkpoint inhibitors; Immune response; Immunology; Immunotherapy; Inflammation; Investigations; Ipilimumab; Kinases; Leukocytes (neutrophilic); Ligands; Liver cancer; Lung cancer; Lymphocytes; Lymphocytes T; Lymphoma; Malignancy; Medical prognosis; Medical research; Melanoma; Meta-analysis; Metastasis; Monoclonal antibodies; Mutation; Nivolumab; Non-small cell lung cancer; Non-small cell lung carcinoma; Pembrolizumab; Peripheral blood; Population studies; Prognosis; Regulation; Review; Small cell lung carcinoma; Solid tumors; Suppressor cells; Systematic review; T cells; Targeted cancer therapy; Tumors; Philippines; neutrophil-to-lymphocyte ratio; inflammation; biomarkers; immunotherapy

Systemic inflammation is associated with prognosis in solid tumors. The neutrophil-to-lymphocyte ratio (NLR) is a marker for the general immune response to various stress stimuli. Studies have shown correlation of NLR to outcomes in immune checkpoint blockade, peripheral neutrophil count to intratum...